Provided By GlobeNewswire
Last update: May 12, 2025
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling
First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026
Read more at globenewswire.com